ADAP241220P7500
- 0.00
- 0.000.00%
Adaptimmune Therapeutics Newsroom
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim
Express News | Adaptimmune Therapeutics PLC : Guggenheim Cuts Target Price to $3 From $4
Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) Have Lost 86%, as Stock Drops 26% This Past Week
Wells Fargo Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Adaptimmune Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Express News | Adaptimmune Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
TD Cowen Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating
Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Cuts Target Price to $3.5
Express News | Adaptimmune Therapeutics PLC : H.c. Wainwright Cuts Target Price to $3.5 From $4
Adaptimmune Therapeutics Plc (ADAP) Q3 2024 Earnings Call Transcript Summary